|
Post by BlueCat on Jan 25, 2015 11:35:01 GMT -5
I am sure Doctors will have samples to give to patients and for demestration in their office. I wonder who pays the budget for samples. Gotta be SNY in that case. Its a sales tool. However, those samples usually have special packaging. Like 1 or 2 doses only. Not a whole box. In which case, MNKD would have to participate in creating it, though SNY would still buy it from them same as other stock.
|
|
|
Post by kc on Jan 25, 2015 12:11:16 GMT -5
Newbie poster buying Afrezza at a Valencia pharmacy does not pass the smell test here with me unless he shows more proof of purchase. A receipt the contents of the box all in one single photo. Afrezza might be in stores now but have any Dr. Starting writing prescriptions? This has set my BS meter off. My apology for coming across harshly as I am just an overzealous Shareholder. this is sketchy seriously how did you get a script if your not diabetic?
|
|
|
Post by liane on Jan 25, 2015 12:20:37 GMT -5
I believe you don't need an Rx for insulin. Obviously, insurance won't pay for it without the Rx. There are conceivably many ways the OP could have obtained a box of Afrezza, especially if paying out of pocket.
|
|
|
Post by bion61 on Jan 25, 2015 12:28:00 GMT -5
I believe you don't need an Rx for insulin. Obviously, insurance won't pay for it without the Rx. There are conceivably many ways the OP could have obtained a box of Afrezza, especially if paying out of pocket. I wish I was that good with Lego, But Liane is correct.
|
|
|
Post by gamblerjag on Jan 25, 2015 12:48:53 GMT -5
I agree that this is false statement until someone shows a receipt but in actuality it really doesn't matter if launch is stated by MNKD/SNY this week... were talking a few days.. I would think a statement would come out prior to it being available to public via insurance or cash out of pocket.
|
|
|
Post by spiro on Jan 25, 2015 13:02:15 GMT -5
|
|
|
Post by liane on Jan 25, 2015 13:08:36 GMT -5
Don't know where Afrezza falls in this. It's not an analogue, but it is a new way to deliver. I was almost tempted to go down to the local pharmacy and check it out.
|
|
|
Post by Chris-C on Jan 25, 2015 13:21:22 GMT -5
I agree that this is false statement until someone shows a receipt but in actuality it really doesn't matter if launch is stated by MNKD/SNY this week... were talking a few days.. I would think a statement would come out prior to it being available to public via insurance or cash out of pocket. With the number of practical jokes that have been played on this board, and given the vast amount of false information being circulated, I think some of these posts must be viewed with the same level of due diligence and skepticism that is appropriate for articles by AF, Orelli, and countless Seeking Alpha offerings. Facts we do know: 1) Afrezza will be launched by Sanofi in the first quarter of 2015; (2) Mannkind met its first production milestone, and product is ready and stocked. Many of us have waited what seems like eons for actual sales to begin; but further patience seems warranted. This drug will become a success; but my own expectation is that it won't happen quickly. I would love to be proven wrong, but my sense is that this will take awhile to gain momentum, as the adoption of some innovations often do. Prandial insulin users won't switch their regimens in haste, especially with the need for physician experience with dosing options. For these and many other reasons, I don't have great expectations for dramatic share price improvement based on sales until 2016. Unless initial sales figures are eye popping, I expect short sentiment to spin the first sales figures with a negative vengeance. I'm holding cash for accumulation under that scenario. Also, not intending to be a nay sayer, I recall with some chagrin an investment I had in Amylin that took a permanent nose dive after the launch of the GLP drug Byetta. There were two problems, actually. The first was one where demand outstripped supplies and the company had to limit distribution (inexcusable). The second was a still unxplained press release from the FDA making a claim that Byetta was associated with acute Pancreatitis. That dropped the share price to a level from which it never recovered and necessitated a study, which showed that the drug actually lowered the incidence of pancreatitis. Bottom line, where there is money involved, never underestimate the dirty deeds possible by miscreants without morals. Investing in biopharma startups is not for the squeamish. GLTA Chris C
|
|
|
Post by kc on Jan 25, 2015 13:26:24 GMT -5
Spiro, this is is from that web site. "In all states new, insulin analogs DO require a prescription. These include Humalog, Novolog, or Apidra, as well as Lantus."
|
|
|
Post by spiro on Jan 25, 2015 13:37:18 GMT -5
Thanks KC, so now I will just have to go to one of the numerous non English speaking clinics down here and get an Rx for Afrezza. It will be no more difficult than getting a handicap parking permit.
|
|
|
Post by kc on Jan 25, 2015 13:47:28 GMT -5
Glad we can still buy OUZO over the counter. I'm reade to celebrate win you soon.
|
|
|
Post by bion61 on Jan 25, 2015 14:32:30 GMT -5
So, do you guys think I made it on my 3D printer?
|
|
|
Post by 1 percenter on Jan 25, 2015 14:45:58 GMT -5
So, do you guys think I made it on my 3D printer? I think you need to do what kidnappers do and take out the actual sealed units from the box and put it next to today's paper with today's date. Then take a picture and post it. Then we will have actual proof of life...er I mean afrezza.
|
|
|
Post by liane on Jan 25, 2015 14:52:13 GMT -5
I don't know bion - these guys are sure giving you a hard time.
|
|
|
Post by jpg on Jan 25, 2015 15:03:19 GMT -5
Hi Bion,
I personally see no reason to doubt the Afrezza box purchase info. It seems to fit in with other sources we have had so far and eventually Afrezza has to get to market. I just think we have reached the 'eventually' point and as long time shareholders many are nervous and skeptical of this new and uncharted territory. It has been a long long time for many of us and we are simply starting the 3rd inning in all this.
JPG
|
|